자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication do not work for many patients suffering from depression. A customized treatment may be the solution.

Cue is an intervention platform that transforms sensors that are passively gathered from smartphones into personalised micro-interventions for improving mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is the leading cause of mental illness across the world.1 Yet, only half of those suffering from the condition receive treatment. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to respond to certain treatments.

Personalized depression treatment is one method to achieve this. Utilizing sensors on mobile phones, an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. With two grants totaling over $10 million, they will employ these techniques to determine biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research on predictors for depression treatment effectiveness (look at this website) has been focused on clinical and sociodemographic characteristics. These include factors that affect the demographics like age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

While many of these aspects can be predicted from data in medical records, very few studies have employed longitudinal data to determine predictors of mood in individuals. A few studies also consider the fact that moods can vary significantly between individuals. It is therefore important to develop methods which permit the identification and quantification of individual differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to recognize patterns of behaviour and emotions that are unique to each person.

The team also devised a machine-learning algorithm that can create dynamic predictors for the mood of each person's depression. The algorithm blends these individual differences into a unique "digital phenotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied significantly between individuals.

Predictors of symptoms

Depression is the leading cause of disability in the world1, however, it is often untreated and misdiagnosed. Depressive disorders are often not treated due to the stigma associated with them, as well as the lack of effective interventions.

To help with personalized treatment, it is important to identify predictors of symptoms. Current prediction methods rely heavily on clinical interviews, which are not reliable and only detect a few features associated with depression.

Machine learning can improve the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing depression treatment in pregnancy Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements. They also capture a wide variety of distinct behaviors and patterns that are difficult to record using interviews.

The study enrolled University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. who were enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were directed to online support or to clinical treatment depending on the degree of their depression. Patients who scored high on the CAT-DI of 35 65 were given online support by the help of a coach. Those with scores of 75 were routed to in-person clinical care for psychotherapy.

At baseline, participants provided an array of questions regarding their personal characteristics and psychosocial traits. The questions included age, sex, and education and marital status, financial status and whether they were divorced or not, their current suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. Participants also rated their level of depression severity on a scale of 0-100 using the CAT-DI. CAT-DI assessments were conducted each other week for the participants that received online support, and every week for those who received in-person support.

Predictors of Treatment Response

Research is focused on individualized depression treatment. Many studies are focused on finding predictors that can aid clinicians in identifying the most effective drugs to treat each patient. Particularly, pharmacogenetics can identify genetic variants that determine how depression is treated the body's metabolism reacts to antidepressants. This lets doctors choose the medications that are likely to be the most effective for every patient, minimizing the amount of time and effort required for trial-and error treatments and avoid any negative side negative effects.

Another promising approach is building models for prediction using multiple data sources, such as the clinical information with neural imaging data. These models can be used to identify the variables that are most predictive of a particular outcome, like whether a medication will help with symptoms or mood. These models can be used to predict the response of a patient to treatment, allowing doctors to maximize the effectiveness.

A new generation uses machine learning methods such as algorithms for classification and supervised learning, regularized logistic regression and tree-based methods to combine the effects of several variables to improve the accuracy of predictive. These models have proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming more popular in psychiatry and could become the standard of future medical practice.

In addition to prediction models based on ML, research into the underlying mechanisms of depression is continuing. Recent findings suggest that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that a individualized treatment for depression will depend on targeted therapies that restore normal function to these circuits.

Internet-delivered interventions can be an option to achieve this. They can offer more customized and personalized experience for patients. For example, one study found that a program on the internet was more effective than standard care in reducing symptoms and ensuring a better quality of life for those with MDD. A randomized controlled study of a personalized treatment for depression revealed that a substantial percentage of patients saw improvement over time as well as fewer side effects.

Predictors of side effects

In the treatment of depression one of the most difficult aspects is predicting and identifying which antidepressant medications will have very little or no adverse effects. Many patients are prescribed a variety medications before finding a medication that is safe and effective. Pharmacogenetics provides an exciting new way to take an effective and precise approach to selecting antidepressant treatments.

Several predictors may be used to determine which antidepressant to prescribe, including gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and comorbidities. To identify the most reliable and reliable predictors for a particular treatment, controlled trials that are randomized with larger samples will be required. This is because the identifying of interactions or moderators could be more difficult in trials that consider a single episode of treatment per person instead of multiple episodes of treatment over time.

Furthermore, the prediction of a patient's reaction to a particular medication will also likely require information on comorbidities and symptom profiles, in addition to the patient's prior subjective experience with tolerability and efficacy. There are currently only a few easily identifiable sociodemographic variables and clinical variables are consistently associated with response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

There are many challenges to overcome in the use of pharmacogenetics to treat depression. First it is necessary to have a clear understanding of the underlying genetic mechanisms is required and an understanding of what treatment for depression is a reliable predictor of treatment response. Additionally, ethical issues, such as privacy and the ethical use of personal genetic information must be considered carefully. In the long-term, pharmacogenetics may offer a chance to lessen the stigma that surrounds mental health treatment and to improve the treatment outcomes for patients with depression. Like any other psychiatric treatment it is essential to take your time and carefully implement the plan. At present, the most effective option is to offer patients various effective medications for depression and encourage them to speak with their physicians about their concerns and experiences.